186
Participants
Start Date
May 29, 2014
Primary Completion Date
April 30, 2025
Study Completion Date
May 26, 2025
Pomalidomide
Dexamethasone
Daratumumab
Local Institution - 149, The Bronx
Local Institution - 129, Glens Falls
Local Institution - 103, Westminster
Local Institution - 130, Durham
Local Institution - 145, Jacksonville
Local Institution - 127, Orlando
Local Institution - 133, Pembroke Pines
Local Institution - 136, St. Petersburg
Local Institution - 131, Nashville
Local Institution - 135, Chattanooga
Local Institution - 124, Louisville
Local Institution - 123, Cleveland
Local Institution - 121, Cleveland
Local Institution - 122, Mayfield Heights
Local Institution - 115, Cleveland
Local Institution - 146, Gross Pointe
Local Institution - 110, St Louis
Local Institution - 102, Kansas City
Local Institution - 134, Fairway
Local Institution - 142, Topeka
Local Institution - 143, Plano
Local Institution - 128, Lubbock
Local Institution - 138, Denver
Local Institution - 126, Tucson
Local Institution - 108, Whittier
Local Institution - 104, Pleasant Hill
Local Institution - 106, Spokane
Local Institution - 137, Greenbrae
Local Institution - 109, Los Angeles
Local Institution - 120, Stamford
Local Institution - 118, East Orange
Local Institution - 101, Hackensack
Local Institution - 107, Hershey
Local Institution - 113, Calgary
Local Institution - 144, Surrey
Local Institution - 114, Vancouver
Local Institution - 139, Moncton
Local Institution - 140, St. John's
Local Institution - 112, Toronto
Local Institution - 148, Toronto
Local Institution - 117, Montreal
Local Institution - 205, Fukuoka
Local Institution - 208, Kamogawa
Local Institution - 204, Kyoto
Local Institution - 202, Nagoya
Local Institution - 203, Okayama
Local Institution - 206, Shibukawa-shi, Gunma-ken
Local Institution - 207, Toyohashi
Local Institution - 119, San Juan
Lead Sponsor
Celgene
INDUSTRY